Magrolimab

Treatment with magrolimab plus docetaxel in metastatic non–small cell lung cancer (mNSCLC) showed peripheral CD47 saturation correlating with improved outcomes. Higher baseline CD47 expression in patients with partial or complete responses led to a median progression-free survival (PFS) of 8.9 months for those with CD47 expression on more than 50% of tumor cells, compared to 2.6 months for those with lower expression. The trial was terminated by Gilead after a global pause in enrollment.

Despite challenges in improving treatment for high-risk myelodysplastic syndrome (HR-MDS), advancements in combination therapies and molecular profiling offer hope. Allogeneic transplantation remains the only curative option, but posttransplant relapse is a concern. Recent trials combining azacitidine with various drugs showed promise but failed to outperform monotherapy in phase 3. Future potential lies in targeted treatments like azacitidine with venetoclax or tamibarotene, and refining response criteria. Molecular findings are crucial for more precise treatment design.

The Global CD47 Inhibitor Drug Clinical Trials Insight & Market Opportunity Outlook 2028 report highlights the emergence of CD47 inhibition as a novel cancer immunotherapy, with multiple candidates in clinical trials, including magrolimab and evorpacept. The market is rapidly evolving, driven by rising cancer incidence and increased use of immunotherapies, with significant commercial interest and notable acquisitions. Challenges include managing toxicity and demonstrating therapeutic advantages over current treatments.